嵌合抗原受体修饰的T细胞疗法回顾

icartab

技术资料下载地址: http://www.ncbi.nlm.nih.gov/pubmed/26797495

文献来源: Semin Immunol

Chimeric antigen receptor-redirected T cellsreturn to the bench.

Abstract

While the clinical progress of chimeric antigenreceptor T cell (CAR-T) immunotherapy has garneredattention to the field, our understanding of the biology of these chimericmolecules is still emerging. Our aim within this review is to bring to lightthe mechanistic understanding of these multi-modular receptors and how theseindividual components confer particular properties to CAR-Ts. In addition, wewill discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population,culturing conditions and additional modifications that enhance their activityparticularly in solid tumors. Finally, we will also consider the emergingtoxicity associated with CAR-Ts. By breaking apart the CAR and examining therole of each piece, we can build a better functioning cellular vehicle for optimizedtreatment of cancer patients.

嵌合抗原受体修饰的T细胞疗法回顾

当嵌合抗原受体修饰的T细胞疗法的临床研究开始受到关注，我们对于这种嵌合分子的生物学认识仍然在积累中。我们这篇综述的目的是对这些多分子受体的作用机制进行理解以及这些独立的组成如何对CAR-T细胞的特性有所影响。此外，我们也讨论了能够影响CAR-T作用的因素，比如CAR-T对于细胞亚群的选择性，培养条件和额外的修改能够增加CAR-T活性尤其是在实体肿瘤中。最后，我们也讨论了与CAR-T相关联的出现的毒副作用。通过将CAR分成部分并且测试每个片段的作用，我们能够建立一个更好功能性细胞来优化治疗癌症患者。

技术资料分享在爱康得生物技术